Skip to main content
ConductScienceScienceDex

Mark B Geyer

NIH Rank #17630
Unclaimed recordClaim profile
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 14135064Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2024

Linked Award Amount
$865.3K
Full award amounts, FY2024
Award Records
1
Records listing this PI
Award-Linked Rank
#17,630
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Mark B Geyer. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Mark B Geyer as a PI. Multi-PI records show the full award amount for context.

  • 5R42CA254685-03R42
    Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
    Actinium Pharmaceuticals, Inc.
    $865.3K
    award amount

Award organization

Organizations that administered FY2024 awards listing Mark B Geyer as a PI.

FY2024 award administered by Actinium Pharmaceuticals, Inc. (NY).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Actinium Pharmaceuticals, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Mark B Geyer.

Anthony Folawuyi Daniyan
Memorial Sloan Kettering Cancer Center
2
shared awards
Avinash Desai
Actinium Pharmaceuticals, Inc.
1
shared award

Explore further

Find collaborators for Mark B Geyer

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →
Mark B Geyer | NIH Award Records | ConductScience